Any new HIV prevention method is not meant to sit on the shelf but to be used by the people who need it to protect themselves ...

From Bettina Bauer, Vice President, US HIV Treatment and Prevention, Gilead Sciences In 2022, there were up to 1.2 million ...

The BRAAVE2020 study investigated the efficacy of switching Black Americans living with HIV to a B/F/TAF single-pill regimen.

Data from a phase Ia clinical trial of an oral, long-acting integrase inhibitor (GS-1720) in development for HIV demonstrated ...

To end the Latino HIV crisis, health programs must be developed, tailored and evolve to meet the health needs and preferences of our diverse Latino communities.

“These incredibly positive outcomes offer new hope at a time when 40 million individuals worldwide are impacted by HIV and ...

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

What caused some of the STD trends to improve? Several experts say one contributor is the growing use of an antibiotic as a ...

Highly effective treatments for HIV have existed since the mid-1990s. But while these treatments keep people healthy, we do not yet have a safe and scalable way to completely rid the body of the virus ...

Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...

Along with concepts like cure, remission, and control, it also helps to understand where vaccines fit in. As Jessica Salzwedel, the senior programme manager for research engagement at New York-based ...

Although sexually transmitted infections are still at an epidemic level in the US, scientists at the US Centers for Disease ...